iShares U.S. Pharmaceuticals ETF news

IHE is presented as the superior choice for many investors due to lower expense ratio (0.37%), significantly higher dividend yield (1.4%), better 5-year total return (79% vs 38%), lower volatility (beta 0.48), and shallower maximum drawdown (-16% vs -35.7%). The article explicitly states 'Many investors may favor IHE.'

Strong recent performance with 38.2% 1-year returns, lower 5-year maximum drawdown of 16%, and concentrated exposure to high-performing Eli Lilly. Positioned as the better choice for investors seeking momentum and direct GLP-1 exposure.

The ETF shows strong recent performance (20.69% YTD, 45.67% 1-year) and low expense ratio (0.37%), but carries elevated risk with high standard deviation (16.8%) and receives a Hold rating from Zacks. The neutral sentiment reflects mixed characteristics suitable for long-term investors but not a strong buy recommendation.

Strong recent 1-year performance (50% return) but underperformed on 3-, 5-, and 10-year returns. More concentrated portfolio with higher risk profile (lower beta of 0.49 indicates less volatility but narrower focus). Not recommended as the better choice despite recent gains.

Criticized for high concentration risk with top 2 holdings (Eli Lilly and J&J) accounting for over 40% of portfolio and top 5 stocks representing 57% of holdings, higher expense ratio (0.37%), and only 56 holdings limiting diversification despite strong 60% one-year returns

Recommended as the better buy for 2026 due to superior 5-year returns (11.8%), better year-to-date performance (17.5% vs 4.7%), and lower maximum drawdown. Higher concentration risk with 56 holdings is offset by stronger recent performance metrics.

Strong recent performance (50.30% 1-yr return) but criticized for high concentration risk with top two holdings representing 43% of portfolio. Outperformance is attributed to a single trend (GLP-1 drugs), making it vulnerable to sector-specific downturns.

Superior 1-year returns (42.40%), lower expense ratio (0.38%), higher dividend yield (1.62%), lower volatility (beta 0.50), and strong year-to-date performance (11% vs -8% for competitor) make it the recommended choice.

Delivered exceptional 39.70% 1-year returns driven by concentrated exposure to GLP-1 drug success; outperformed broader healthcare fund significantly.

Mentioned as another alternative option with comparable expense ratio (0.37%) and largest asset base ($1.57 billion) among the three. No performance metrics or specific recommendations provided.

Presented as a competitive alternative with the lowest expense ratio (0.37%) and highest assets ($1.54 billion) among the three compared ETFs.

Mentioned as an alternative pharma ETF with the largest assets ($1.57 billion) and competitive expense ratio (0.37%), slightly lower than XPH, positioning it as a comparable option.

Listed as an alternative pharma ETF with the largest asset base ($1.60B) and competitive expense ratio (0.37%); presented as equivalent alternative without preference.

Mentioned as a diversified alternative for investors seeking broader exposure to the pharmaceutical sector without concentrating in a single biotech name. No specific sentiment is implied; it is presented as a portfolio diversification option.